Ultrastructural changes of the choroid and retina of rabbits in intravitreal injection of selective and nonselective inhibitors of growth factors of the vascular endothelium

Dumbrova, N.; Korol, A.; Nasinnyk, I.; Kustrin, T.

doi:10.31288/oftalmolzh201236872

Cited by 1 publication

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in agreement with Kohno and colleagues [11] who found that a single intravitreal injection of bevacizumab may induce changes in immature, newly formed vessels of PDR tissue, particularly, by reducing vessel fenestration. In addition, Vidinova and Vidinov [13] examined the effect of bevacizumab on the ultrastructure of choroidal neovascular membranes in patients with age-related macular degeneration (AMD) and also demonstrated that intravitreally administered bevacizumab causes changes in the new vessel walls and in the extracellular matrix components, which diminishes the fenestration of the endothelial cells. Moreover, others [17-19] demonstrated penetration of bevacizumab through the blood retinal barrier after intravitreal injection in the monkey, with subsequent morphological changes in the choriocapillaris.…”

Section: Discussionmentioning

confidence: 99%

“…Vidinova and Vidinov [13] examined the ultrastructural changes in the subretinal neovascular membranes occurring after the intravitreal administration of bevacizumab in patients with age-related macular degeneration (AMD). Subretinal membranes in AMD patients consisted mainly of fibroblasts, isolated or grouped RPE cells and elements of blood [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultrastructural features of epiretinal membranes after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy

Ponomarchuk¹,

Molchaniuk²,

Umanets³

2021

Oftalmol Zh

View full text Add to dashboard Cite

Background: Proliferative diabetic retinopathy (PDR) can cause a loss of vision due to complications like vitreous hemorrhage and tractional retinal detachment, which require vitrectomy. The source of bleeding is usually in pathologic new blood vessels in the fibrovascular epiretinal membrane (ERM). Anti-vascular endothelial growth factor agents are widely used for prevention of intraoperative and postoperative hemorrhagic complications in vitrectomy for PDR. Purpose: To examine ultrastructural features of ERM after intravitreal injection of various doses of aflibercept in patients with PDR.Material and Methods: Five patients (5 eyes) were included in the study. ERM specimens with neovascular vessels were taken intraoperatively from the five patients for histological microscopy studies. Specimen No. 1 was taken from the ERM (control ERM) of the patient who did not receive preoperative injection of aflibercept. In addition, specimen No. 2 was taken on day 3 after intravitreal injection of 1.0 mg aflibercept; specimen No. 3, on day 5 after intravitreal injection of 1.0 mg aflibercept; specimen No. 4, on day 3 after intravitreal injection of 2.0 mg aflibercept; and specimen No. 5, on day 5 after intravitreal injection of 2.0 mg aflibercept. Results: We found that aflibercept had a positive effect on obliteration of newly formed vessels and capillaries. There was a decrease in the size of the lumen of ERM microvessels with an increase in the injected dose and time after injection. In addition, endothelial cells in the newly formed vessels and fibroblasts exhibited active protein synthesis metabolism on day 3 after intravitreal injection of 1.0 mg aflibercept or 2.0 mg aflibercept.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%